Revisiting PD-1 to target leukaemic stem cells

PD-1 and PD-L1 are important immune checkpoint molecules that modulate T cell activity. A study now shows that PD-1 marks leukaemia stem cells (LSCs) in T cell acute lymphoblastic leukaemia and reveals therapeutic opportunities to target LSCs via anti-PD-1 therapy.